NZ743659A - Crystalline forms of thienopyrimidine compound - Google Patents
Crystalline forms of thienopyrimidine compoundInfo
- Publication number
- NZ743659A NZ743659A NZ743659A NZ74365916A NZ743659A NZ 743659 A NZ743659 A NZ 743659A NZ 743659 A NZ743659 A NZ 743659A NZ 74365916 A NZ74365916 A NZ 74365916A NZ 743659 A NZ743659 A NZ 743659A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystalline form
- peaks
- formula
- compound
- irradiated
- Prior art date
Links
- -1 thienopyrimidine compound Chemical class 0.000 title description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims description 55
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 20
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 13
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 6
- 102100010782 EGFR Human genes 0.000 claims description 5
- 101700039191 EGFR Proteins 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 150000004683 dihydrates Chemical class 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 150000004684 trihydrates Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 4
- FDMQDKQUTRLUBU-UHFFFAOYSA-N N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 abstract description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000002844 melting Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 230000035492 administration Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- 238000004450 types of analysis Methods 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004441 surface measurement Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-N,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Chemical class OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 241001415961 Gaviidae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Chemical class 0.000 description 1
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000010405 anode material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000011031 large scale production Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention relates to crystalline forms of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and pharmaceutical compositions containing the same. The crystalline forms can be easily used for the preparation of a pharmaceutical composition containing the same as an active ingredient. taining the same as an active ingredient.
Description
Description
Title of Invention: CRYSTALLINE FORMS OF THIENOPY-
RIMIDINE COMPOUND
Technical Field
The present invention relates to crystalline forms of a thienopyrimidine compound
and pharmaceutical compositions containing the same. More specifically, the present
invention relates to crystalline forms of N —
(3-(2—(4—(4—methylpiperazin—1—yl)phenylamino)thieno[3,Z—d]pyrimidin—4—yloxy)phenyl
)acrylamide, and ceutical itions containing the same.
Background Art
The compound of Formula 1 below, whose compound name is N —
(3-(2—(4—(4—methylpiperazin—l—yl)phenylamino)thieno[3,2—d]pyrimidin—4—yloxy)phenyl
amide {INN2 2—propenamide, N —
[3— [[2—[[4—(4—methyl— razinyl)phenyl] amino]thieno[3,2—d]pyrimidin—4—yl]oxy]phe
nyl] }, is disclosed in PCT application . The compound has a
selective inhibitory ty for a mutant epidermal growth factor receptor tyrosine
kinase.
[Formula 1]
\N/fi COMM
K/N H
N” S
WI /
Additionally, the above reference discloses the method of preparing the compound of
Formula 1.
However, the nd of Formula 1 prepared in the above cited references was
prepared as an amorphous solid, which is a form generally less suitable for a large—
scale production of pharmaceutical drugs. For example, the thus-prepared form of the
compound of Formula 1 was insufficient in the aspects of stability and non—
hygroscopicity for pharmaceutical formulations.
ingly, there is a need for the development of the compound of Formula 1 in
crystalline forms which can fully comply with the strict ements and details
thereof regarding pharmaceutical solid forms and formulations. onally, the
compound of Formula 1 is preferably in a form that affords facile handling of the
product upon sis such as ease of filtration and drying, and also for the e of
economy, preferably enables long—term stable maintenance of a crystalline form
t requiring particular storage conditions.
Under these circumstances, the present ors have made intensive efforts to
develop a novel crystalline form of the compound of Formula 1, and have discovered
that a particular crystalline form can provide excellent overall physicochemical
properties such as stability, non-hygroscopicity, etc., and thus it can be easily used for
the preparation of a pharmaceutical composition containing the same as an active in—
nt, thereby completing the present invention.
Disclosure of Invention
Technical Problem
An object of the present invention is to provide a crystalline form of the compound
of Formula 1, and a pharmaceutical ition containing the same.
Solution to Problem
In order to achieve the above object, in one aspect of the t invention, there are
provided crystalline forms of the compound of Formula 1 as shown below:
[Formula 1]
OQNMo \N’fi
K/N H
N” S
WI /
Specific examples of the above crystalline forms are as shown below:
A crystalline form of a compound of Formula 1 having an X—ray powder ction
(XRPD) pattern comprising peaks at diffraction angles of 26 = 8.6% 0.20, 16.0% 0.20
and 17.2% 0.20 when irradiated with a Cu—Kor light source. This crystalline form may
further comprise diffraction peaks at 26 = 9.4% 02", 10.3% 0.20, 13.7% 0.20, 17.9%
0.20, 19.7% 02°, 22.1% 0.20, 23.6% 0.20, and 26.4% 0.20 when irradiated with a Cu-
KOL light source;
A crystalline form of a compound of a 1 having an X—ray powder diffraction
(XRPD) pattern comprising peaks at diffraction angles of 26 = 5.3% 02" and 16.2%
0.20 when irradiated with a Cu-KOt light source. This crystalline form may further
comprise diffraction peaks at 26 = 20.7°i 0.20 when irradiated with a Cu—Ka light
source;
A crystalline form of a nd of a 1 having an X—ray powder diffraction
(XRPD) pattern sing peaks at diffraction angles of 26 = 3.8% 02" and 11.6%
0.20 when irradiated with a Cu-Ka light source. This crystalline form may further
comprise diffraction peaks at 26 = 980$ 02", l6.9°i 0.2°, and 19.8% 0.20 when irradiated
with a Cu—Ka light source; and
A crystalline form of a compound of Formula 1 having an X-ray powder diffraction
(XRPD) pattern sing peaks at ction angles of 26 = 11. l°i 02°, 20.3%
0.20 and 20.8% 02" when irradiated with a Cu-Ka light source. This lline form
may further comprise diffraction peaks at 26 = 14.601L 0.20, 15.5% 0.20, 21.0°i 0.20,
and 22.2°i 02" when irradiated with a Cu—Ka light source.
In another , each crystalline form of the compound of Formula 1 as described
herein is in substantially pure form.
The term "substantially pure" as used herein means at least 95% pure, preferably
99% pure, where 95% pure means not more than 5%, and 99% pure means not more
than 1%, of any other form of the compound of Formula 1 being t (other
crystalline form, amorphous form, etc).
In r aspect of the present invention, there is provided a pharmaceutical com—
position containing any one selected from the above crystalline forms and at least one
ceutically acceptable carrier and/or diluent.
The pharmaceutical composition can be used for the treatment of cancer induced by
epidermal growth factor receptor tyrosine kinase or a mutant thereof.
Advantageous Effects of ion
The crystalline forms of the nd of Formula 1 according to the present
invention have excellent overall physicochemical characteristics, and thus the
crystalline forms can be easily used for the preparation of a pharmaceutical com—
position containing the same as an active ingredient.
Brief Description of Drawings
FIGS. la to 1d show X—ray powder diffraction (XRPD) patterns of crystalline forms
of the compound of Formula 1 prepared in Examples 1 to 4 of the present invention.
FIG. le shows an X—ray powder diffraction (XRPD) pattern of an amorphous form of
the compound of Formula 1 prepared in Comparative Example 1 of the present
invention.
FIGS. 2a to 2d show the graphs of differential scanning calorimetry (DSC) of
crystalline forms of the compound of Formula 1 prepared in Examples 1 to 3 of the
present invention.
shows the graph of differential scanning calorimetry (DSC) of an amorphous
form of the compound of Formula 1 prepared in Comparative Example 1 of the present
invention.
FIGS. 3a to 3d show the graphs of dynamic vapor sorption (DVS) of crystalline
forms of the compound of Formula 1 prepared in Examples 1 to 3 of the present
invention.
shows the graph of dynamic vapor sorption (DVS) of an amorphous form of
the compound of Formula 1 prepared in Comparative Example 1 of the present
invention.
Mode for the ion
Hereinafter, the present ion will be bed in more detail with reference to
the ing Examples. However, these Examples are for illustrative es only,
and the invention is not intended to be d by these Examples.
Unless otherwise defined, all terms ing technical and scientific terms used
herein have the same meanings as commonly understood within the t by one of
ordinary skill in the art to which the invention belongs. However, unless otherwise
specified, the term described below will have the meaning indicated below over the
entire specification:
As used herein, the term " refers to being within 5% of a particular value or
range, and more preferably within 1% to 2%. For example, "about 10%" refers to 9.5%
to 10.5%, and preferably, 9.8% to 10.2%. For another example, "about 100°C" refers to
95°C to 105°C, and preferably, 98°C to 102°C.
Unless otherwise specified, it must be apparent to a skilled practitioner that the
values of peaks from X—ray powder diffraction studies reported in this invention are as—
sociated with experimental errors typically observable in this field. ically, a peak
is interpreted as to be located within i0.5° of the value reported herein. More
specifically, a peak is interpreted as to be located within i0.2° of the value reported
Crystalline forms of the compound of Formula 1
The present invention provides a crystalline form of the compound of Formula 1
below, i.e., N-(3-(2-(4-(4-methylpiperazinyl)phenylamino)thieno[3,2-d
]pyrimidin—4—yloxy)phenyl)acrylamide:
[Formula 1]
\N/fi OQNMO
K/N H
IV] S
The compound of Formula 1 above (free base) may be prepared according to the con—
ventional procedure described in , which is hereby incorporated by
reference in its entirety.
The compound of Formula 1 may be prepared in a crystalline or amorphous form or
a mixture thereof, and preferably in a lline form because the crystalline form has
excellent stability and non—hygroscopicity, and thus has a physicochemical property
which facilitates its formulation.
According to the present invention, the compound of Formula 1 can be prepared in
various crystalline forms, and each of the possible crystalline forms will be described
in detail herein below.
In one embodiment of the present ion, provided are crystalline forms of the
compound of Formula 1. In a particular embodiment of the present invention, these
lline forms are anhydrous. In r particular embodiment, the crystalline
forms are hydrates. In a further specific embodiment, this hydrate is a dihydrate. In yet
another specific ment, the crystalline form is a rate.
In an exemplary embodiment, the t invention provides a crystalline dihydrate
form (Form A) of the compound of Formula 1. Form A exhibits an XRPD pattern
comprising peaks at 26 = 8.6Oi0.2°, 16.00i0.2O and 17.2°i0.2O when irradiated with a
Cu-ch light . More specifically, the crystalline form has an XRPD pattern
comprising peaks at diffraction angles of 26 = 8.6Oi0.2°, 9.4Oi0.2°, 0.2°,
13.7°i0.2°, 16.0°iO.2°, 17.2°i0.2°, 17.9°i0.2°, 19.7Oi0.2°, 22.1°i0.2°, 23.6°i0.2°,
and 26.4"i0.2O when irradiated with a Cu—Kd light source. More specifically, the
above crystalline form (Form A) of the compound of Formula 1 has an XRPD pattern
comprising peaks at diffraction angles of 26 = 8.6Oi0.2°, .2°, 10.30i0.2°,
13.7°i0.2°, 0.2°, 17.2Oi0.2°, 17.9°i0.2°, 19.7Oi0.20, 22.1Oi0.2°, 22.3°i0.2°,
23.2Oi0.2°, 0.2°, 26.4Oi0.2°, 29.7Oi0.2°, and 35.30i0.2° when irradiated with a
Cu—Kor light source. These peaks may be those having a relative intensity (MD) of
about 20% or more.
The above crystalline form may have an endothermic peak which has a starting point
at about 75°C and its lowest point at about 93°C, an exothermic peak which has a
starting point at about 141°C and its highest point at about 149°C, and an endothermic
peak which has a starting point at about 199°C and its lowest point at about 205°C, in a
DSC (10°C/min).
The above crystalline form may have a melting point of about 203°C to 204°C.
The above crystalline form may have an tion amount of about 1.5% to 2.5% in
the region with a ve humidity of 10% to 90%, in a DVS.
In another exemplary embodiment, the present invention provides a trihydrate
crystalline form (Form B) of the compound of Formula 1. Form B exhibits an XRPD
pattern comprising peaks at 26 = 5 2° and l6.2°i0.2° when irradiated with a Cu—
KOL light source. More specifically, the crystalline form has an XRPD pattern
comprising peaks at diffraction angles of 20 = 5.3°i0.2°, 16.2°i0.2°, and 20.7°i0.2°
when irradiated with a Cu—Ka light source. More specifically, the above crystalline
form (Form B) of the compound of Formula 1 has an XRPD pattern comprising peaks
at diffraction angles of 20 = 5.3°i0.2°, l6.2°J_r0.2°, 20.7°i0.2°, 25.4°i0.2°, and
28.5°i0.2° when irradiated with a Cu—Kor light . These peaks may be those
having a relative intensity (1/10) of about 7% or more.
The above lline form may have an ermic peak which has a ng point
at about 74°C and its lowest point at about 95°C, an exothermic peak which has a
starting point at about 136°C and its highest point at about 145°C, and an endothermic
peak which has a starting point at about 195°C and its lowest point at about 203°C, in a
DSC (10°C/min).
The above crystalline form may have a melting point of about 204°C to 205°C.
The above crystalline form may have an absorption amount of about 5% to 6% in the
region with a relative humidity of 10% to 90%, in a DVS.
In still r exemplary embodiment, the present invention provides an ous
lline form (Form C) of the compound of Formula 1. Form C exhibits an XRPD
pattern comprising peaks at 20 = 3.8°iO.2° and ll.6°i0.2° when irradiated with a Cu—
Koz light source. More specifically, the crystalline form has an XRPD pattern
comprising peaks at diffraction angles of 20 = 3.8°i0.2°, 9.8°i0.2°, ll.6°i0.2°,
16.9°i0.2°, and 19.8°i0.2° when irradiated with a Cu—Ka light source. More
specifically, the above lline form (Form C) of the compound of Formula 1 has an
XRPD pattern comprising peaks at diffraction angles of 20 = 3.8°i-0.2°, 9.8°i0.2°,
ll.6°i0.2°, l6.9°i0.2°, 19.8°i0.2°, 20.2°i0.2°, 2l.9°i0.2°, 24.3°i0.2°, and 247°
when irradiated with a Cu—Ka light . These peaks may be those having a relative
intensity (1/10) of about 7% or more.
The above crystalline form may have an endothermic peak which has a starting point
at about 194°C and its highest point at about 207°C in a °C/min).
The above crystalline form may have a melting point of about 204°C to 205°C.
The above lline form may have an tion amount of 0.9% to 1.1% in the
region with a relative ty of 10% to 90%, in a DVS.
In still another exemplary embodiment, the present invention also provides an
anhydrous crystalline form (Form D) of the compound of Formula 1. Form D exhibits
an XRPD pattern comprising peaks at 20 = 11.1°iO.2°, 20.3°i0.2° and 20.8°i0.2°
when irradiated with a Cu—Kd light source. More specifically, the crystalline form has
an XRPD pattern comprising peaks at diffraction angles of 20 = ll.1°i0.2°,
l4.6°i0.2°, 15.5°i0.2°, 20.3°i0.2°, 20.8°i0.2°, 21.0°i0.2°, and 22.2°i0.2° when irradiated
with a Cu—Ka light source. More specifically, the above crystalline form
(Form D) of the compound of Formula 1 has an XRPD pattern comprising peaks at
diffraction angles of 20 = 8.8°i—0.2°, 10.5°iO.2°, ll.1°i0.2°, 14.6°i—0.2°, 15.5°i0.2°,
l7.5°i0.2°, l9.2°i0.2°, l9.4°i0.2°, 20.3°i0.2°, 20.8°i0.2°, 21.0°i0.2°, 22.2°i0.2°,
23.1°i0.2°, 23.4°J_r0.2°, 25.0°i0.2°, and 25.2°i0.2° when irradiated with a Cu-Ka
light . These peaks may be those having a relative intensity (MD) of about 10%
or more.
The above crystalline form may have an ermic peak which has a starting point
at about 204°C and its highest point at about 208°C in a DSC (10°C/min).
The above crystalline form may have a melting point of about 204°C to 205°C.
The above crystalline form may have an tion amount of 0.2% to 0.5% in the
region with a relative humidity of 10% to 90%, in a DVS.
Medical use and pharmaceutical composition
As disclosed in , the compound of Formula 1 has been shown to be
useful for the selective and effective inhibitory activity against the growth of cancer
cells and induced by a mutation in epidermal growth factor or (EGFR) tyrosine
kinase or a mutant thereof, and drug resistance thereof.
In one aspect the ion further provides a crystalline form of the compound of
Formula 1 as described herein for use in the treatment of a cancer harboring one or
more EGFR mutation.
In a further aspect the ion provides a method for the treatment of cancer
comprising administering to a patient in need thereof a therapeutically effective
amount of a crystalline form of the nd of Formula 1 as described herein,
wherein the cancer to be d is a cancer ing one or more EGFR mutation.
In a further aspect the cancer to be treated is a cancer harboring one or more EGFR
mutations wherein at least one EGFR mutation is selected from De119 ion in
exon 19), L858R and T790M.
In a further aspect the cancer to be treated is a cancer harboring a Dell9 EGFR
mutation.
In a r aspect the cancer to be treated is a cancer harboring the EGFR on
L858R.
In a further aspect the cancer to be treated is a cancer harboring the EGFR mutation
T790M.
In a further aspect the cancer to be treated is a cancer harboring at least two EGFR
mutations selected from the group consisting of De119/T790M and L858RfT790M.
In this aspect, the crystalline forms of the compound of Formula 1 may be used for
the preparation of a pharmaceutical composition for preventing or treating cancers or
tumors d by epidermal growth factor receptor tyrosine kinase or a mutant
f. The pharmaceutical composition may be used to treat the same cancers
ing EGFR mutation as described for the crystalline forms of the compound of
Formula 1 hereinbefore.
Accordingly, the present invention provides a pharmaceutical composition
containing a crystalline form of the compound of Formula 1 and at least one pharma—
ceutically acceptable r or diluent. The pharmaceutical composition may be used
for the treatment of cancers or tumors d by epidermal growth factor receptor
tyrosine kinase or a mutant f.
The administration dose of the crystalline forms of the compound of Formula 1 or a
pharmaceutical composition containing the same may vary depending on the subject to
be treated, severity of illness or health state of the subject, administration rate,
physician's decision, etc, but may be conventionally administered to a human subject
having a body weight of e.g. 70 kg Via an oral or parenteral administration route in an
amount of 10 mg to 2,000 mg as an active ingredient based on the nd of
a 1, preferably in an amount of 50 mg to 1,000 mg, l to 4 times daily or on an
on/off schedule. In some cases, it may be more appropriate to administer a lower
dosage than that mentioned above, a higher dosage than the above may be ad—
ministered if it does not cause harmful side effects, and in the case when a significantly
larger dosage is to be administered, the administration may be performed daily by
several divided doses with a lesser dosage per administration.
The pharmaceutical composition according to the present invention may be prepared
in various ations for oral administration according to the conventional methods,
e.g., tablets, pills, powders, capsules, syrups, emulsions, microemulsions, etc., or for
parenteral stration, e.g., intramuscular, intravenous, or subcutaneous adminis—
trations.
The pharmaceutical composition may contain any tional non—toxic, pharma—
ally acceptable carrier, diluents, adjuvant, excipient, or vehicle.
When the pharmaceutical composition according to the present invention is prepared
as a formulation for oral administration, the carrier to be used may include, e. g.,
cellulose, calcium silicate, corn starch, e, sucrose, dextrose, calcium phosphate,
stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending
agents, emulsifying agents, ts, etc. Additionally, when the pharmaceutical com—
position is ed as a formulation for oral administration, the diluents to be used
may include lactose, mannitol, saccharide, microcrystalline cellulose, cellulose
derivative, corn , etc. When the ceutical composition according to the
present invention is prepared as a formulation for injections, the carrier to be used may
include, e.g., water, saline, an aqueous sugar—like solution, alcohols, ethers (e. g.,
polyethylene glycol 400), oils, fatty acids, fatty acid esters, glycerides, surfactants,
suspending agents, emulsifying agents, etc.
Hereinafter, the present invention will be described in more detail with reference to
the following Examples. However, these Examples are for illustrative purposes only,
and the invention is not intended to be limited by these Examples.
Analysis Apparatus and Method of Measurement
1. X-ray Powder Diffraction (XRPD)
X—ray powder diffraction (XRPD) es of samples were performed in the range
from 3° 20 to 40° 20 using a D8 e r ASX, Germany) analyzer. When the
amount of a given sample was less than 100 mg, about 5 mg to 10 mg of the sample
was gently compressed on a glass slide which was fit into a sample holder. When the
amount of a given sample was greater than 100 mg, about 100 mg of the sample was
gently compressed in a plastic sample holder so that the sample surface became flat
and positioned immediately on top of the sample holder level.
F—lr—lf—lr—lf—lr—lf—lr—lF—lr—lF—lF—l OOOOOOOOOOOOOOOO\]\1\]\] flow-QWNt—‘OOOONQ P—! 00 00 |—l|—l|—l|—l|—l|—l|—l|—l|—l|—d|—d The measurement was performed as follows:
Anode material (K01); Cu—ch (1.54056A)
Scan range: 3° to 40°
Generator settings: 100 mA, 40.0 kV
Scan speed: 1 sec/step
Diver slit: 0.3°
catter slit: 0.3°
ature: 20°C
Step size: 002° 20
Rotation: use
Goniometer radius: 435 mm
2. Differential ng Calorimeter (DSC)
Differential scanning calorimeter (DSC) analysis was performed in as STA—1000
(Scinco, Korea) at 30°C to 350°C. A sample in an amount of 5 mg to 10 mg was
weighed and added into an aluminum DSC fan, and the fan was sealed with a
perforated aluminum lid in a non—sealing manner. Then, the sample was heated at a
scan speed of 10°C/min from 30°C to 350°C, and the heat flow reaction generated was
monitored in a DSC.
3. Dynamic Vapor Sorption (DVS)
Dynamic vapor sorption (DVS) analysis was performed in a DVS age (Surface
measurement system, United Kingdom) analyzer at 25°C with a relative humidity of
0% to 90%. A sample in an amount of 10 mg was placed into a wire-mesh vapor
sorption balance pan and then attached to a DVS advantage c vapor sorption
balance via surface measurement systems. Until a stable weight was achieved (99.5%
completion of steps), the sample was applied to a g profile with a relative
humidity of 10% to 90% with a 10% increase of the sample while maintaining the
sample in each step. Upon completion of the sorption cycle, the sample was dried
using the same process while ining a relative humidity of below 0%. The
changes in the sample weight during the adsorption/desorption cycle (repeated 3 times)
were ed and the hygroscopicity of the sample was measured.
4. High mance Liquid Chromatography (HPLC)
High performance liquid chromatography (HPLC) analysis was performed for the
purposes of ing purity and contents such as a stability test, etc., using an Agilent
1100/1200 series HPLC Systems (Agilent, USA) analyzer, and the conditions used for
HPLC were as follows.
Purity and t analysis conditions: thienopyrimidine compound of Formula 1
Column: Hydrosphere C18 (YMC), 5 um (150 mm x 4.6 mm)
Column temperature: 30°C
Detector: UV spectrophotometer
Detection wavelength: 254 nm
Flow rate: 1.0 mL/min
Time of analysis: 35 min
: NaClO4—NaH2PO4 — phosphate buffer solution (pH 2.5 i 0.1)/CH3CN = 40/60
(v/v%)
. Karl-Fischer Titrator: Metrohm, 795KFT Titrino
6. Melting Point Analyzer: Bastead electro thermal, 9300
7. Nuclear Magnetic Resonance (NMR): BRUKER, Advance DPX 300 (300 MHz)
Preparation of lline forms of a nd of Formula 1
Comparative Example 1: Preparation of an amorphous form of a compound of
Formula 1
An amorphous form of the compound of Formula 1 was obtained according to the
method disclosed in WO 62515, or a similar method thereof, which is reference
herein.
Water content: 0.3%
Melting point: 203°C to 205°C
MS Spectrum: m/z = 487.19 (M+1)
1H-NMR Spectrum (300MHz, DMSO-d6) 6 s, lH), 9.24(s, 1H), 8.27(d, lH),
7.71(d, 1H), 7.64(d, 1H), 7.49-7.41(m, 3H), 7.32(d, 1H), 7.07(dd, 1H), , 2H),
6.42(dd, 1H), 6.28(dd, lH), 5.78(dd, 1H), 2.99(t, 4H), 2.43(t, 4H), 2.2l(s, 3H).
Analysis of characteristics
The results of XRPD, DSC, and DVS analyses of the amorphous form prepared in
Comparative Example 1 are shown in FIGS. le, 2e, and 3e, respectively.
The amorphous form did not show any particular diffraction value in the XRPD
pattern.
Additionally, the amorphous form was shown to have an endothermic peak which
has a ng point at about 537°C and its highest point at about 73.64°C, and an
exothermic peak which has a starting point at about l40.64°C and its highest point at
about 150.l3°C, in a DSC min), and this was expected to be a phase tion.
An endothermic peak was shown at about 205.89°C.
In the DSC, the endothermic peak at about 73.64°C indicates the dehydration point,
and the endothermic peak at about °C indicates a melting point. The melting
point was ed to be between about 204°C and about 205°C.
Additionally, in the DVS, the amorphous form showed a continuous hygroscopic
tendency in the region with a relative humidity of 10% to 90% up to a water content
between about 5% and about 6%, and this is ed to be unstable from the hy—
groscopic aspect.
Example 1: Preparation of a crystalline form (Form A) of a compound of
Formula 1
The title compound prepared in Comparative Example 1 (100 g; 0.21 mol) was added
into a mixed solvent of acetone (400 mL) and water (100 mL), and the mixture was
heated under reflux for 2 hours. Then, the resultant was cooled to 15°C to 20°C or
below, stirred for 12 hours, and the resulting solids were filtered, washed with a mixed
solvent (acetone/water = 4/1), and dried at 50°C to obtain the compound of Formula 1
in a crystalline form (78g, yield: 78%).
Water t: 7.0% (theoretical value of a dihydrate: 6.90%)
Analysis of characteristics
The results of XRPD, DSC, and DVS analyses of the crystalline form prepared in
e 1 are shown in FIGS. la, 2a, and 3a, respectively.
The peaks having a relative intensity (I/Io) of 3% or higher in the XRPD pattern of
the above crystalline form are shown in Table 1 below. When the peaks had I/IO ratios
equal to or higher than 20%, they appeared at diffraction angles of 86°, 94°, 10.3°,
137°, 160°, 172°, 179°, 197°, 221°, 223°, 232°, 236°, 264°, 297°, and 353° (20
i 0.2°).
[Table l]
on (n
45m was“
Additionally, the above crystalline form showed an endothermic peak which has a
starting point at about 75 .05°C and its highest point at about 93.01°C, and an
exothermic peak which has a starting point at about 140.61°C and its highest point at
about 148.80°C, in a DSC (10°C/min), and this was expected to be a phase transition.
Additionally, an endothermic peak which has a starting point at about 198.56°C and its
highest point at about 204.67°C was shown.
In the DSC, the endothermic peak at about 93.01°C indicates the dehydration point,
and the endothermic peak at about 204.67°C indicates a melting point. The melting
point was ed to be between about 203°C and about 204°C.
Additionally, in the DVS, the above lline forms showed a continuous hy—
groscopic tendency in the region with a relative humidity of 10% to 90% up to a water
content of about 1.5%, and this is expected to be stable from the hygroscopic aspect.
Example 2: Preparation of a crystalline form (Form B) of a compound of
Formula 1
The ous form of the compound of a 1 prepared in Comparative
Example 1 (200 g; 0.42 mol) was added into a mixed solvent of acetone (2.2 L) and
water (200 mL), and the mixture was dissolved by heating at 60°C for 1 hour. Then,
the resultant was treated with active carbon, filtered with celite, and washed with
e (400 mL).
The filtrate solution, at between 30°C and 40°C, was treated with water (600 mL),
cooled slowly to room temperature, stirred for 3 hours, cooled again to a temperature
between 5°C and 10°C, and d for 2 hours.
The ormed solids were filtered, washed with a mixed solvent (300 mL) of
e and water (v/v = 2.5/1), and dried at 50°C to obtain the compound of Formula
1 in a crystalline form (152.0 g, yield: 76.0%).
Water content: 9.8% (theoretical value of a trihydrate: 10.0%)
Analysis of characteristics
The results of XRPD, DSC, and DVS analyses of the crystalline form prepared in
Example 2 are shown in FIGS. 1b, 2b, and 3b, respectively.
The peaks having a relative intensity (MD) of 3% or higher in the XRPD pattern of
the above crystalline forms are shown in Table 2 below. When the peaks had I/IO ratios
equal to or higher than 7%, they appeared at diffraction angles of 53°, 162°, 207°,
254°, and 28.5°(20 i 0.2°).
[Table 2]
29 (10.2) “5 1/10 (as) 29 (520.2)
100 24 o
—20 5 25 4
29' diffraction 2111316, (1' distance between crystal faces.
1/10 ($13 relative intensity (1 indicates the intensity of each peak; L, indicate
Additionally, the above crystalline form showed an endothermic peak which has a
ng point at about 74.17°C and its lowest point at about 95 .38°C, and an
exothermic peak which has a starting point at about 135.8 1°C and its highest point at
about 145.45°C, in a DSC (10°C/min), and this was expected to be a phase transition.
Additionally, an endothermic peak which has a starting point at about 194.71°C and its
highest point at about 202.96°C was shown.
In the DSC, the endothermic peak at about 95.38°C indicates the dehydration point of
the crystalline form of ate of the compound of Formula 1, and the ermic
peak at about 194.71°C indicates a g point. The melting point was measured to
be n about 204°C and about 205°C.
Additionally, in the DVS, the above crystalline forms showed a copic
tendency in the region with a relative humidity of 10% to 90% up to a water content
between about 5% and about 5.5%.
Example 3: ation of a crystalline form (Form C) of a compound of
Formula 1
The title compound (5.0 g) obtained in Comparative Example 1 was dried at 170°C
using a weight—reducing drying device (LOD) for 30 s to remove water, and the
nd of Formula 1 was obtained in a crystalline form.
Analysis of characteristics
The results of XRPD, DSC, and DVS analyses of the crystalline form prepared in
Example 3 are shown in FIGS. 1c, 2c, and 3c, respectively.
2016/015536
The peaks having a relative intensity (Me) of 3% or higher in the XRPD n of
the above crystalline forms are shown in Table 3 below. When the peaks had I/IO ratios
equal to or higher than 7%, they appeared at ction angles of 38°, 98°, 116°,
169°, 198°, 202°, 219°, 243°, and 247° (20 i 0.2°).
[Table 3]
29 “1:02) (1
3.8 23.1 .
: 8.5 10.41 . .
“.m- ‘ .0 _. .
2 . . '. .
6.8 3.7 24.3 .
18.7 4.8 32 3 26 5 3.4
—_—|_ 2.9
26: diffraction angle, d2 distance between crystal faces,
1/10 (is): relative intensity (I indicates the intensity of each peak; L, indicate
he intensity of the highest peak.
Additionally, the above crystalline form showed an endothermic peak which has a
starting point at about 193.69°C and its highest point at about 207.25°C in a DSC
(10°C/min). In the DSC, the endothermic peak indicates the dehydration point. The
melting point was measured to be n about 204°C and about 205°C.
Additionally, in the DVS, the above crystalline form showed the hygroscopic level of
about 0.8% to about 0.9% in the region with a relative humidity of 10% to 90%. From
these results, the above crystalline forms were expected to be very stable from the hy—
groscopic . Additionally, from these results, it was confirmed that they were very
stable under a long—term storage condition (a temperature of 25°C and a relative
humidity of 60%) and an accelerated condition (a temperature of 40°C and a relative
humidity of 75%).
Example 4: Preparation of a crystalline form (Form D) of a compound of
Formula 1
The title nd (5.0 g) ed in Examples 1 and 2 were added into iso—
propanol (50 mL) and heated under reflux for 2 hours. Then, the reaction mixture was
cooled to room temperature and stirred for 3 hours, and the resulting solids were
filtered, washed with isopropanol (10 mL), dried at 50°C, and the compound of
Formula 1 was obtained in an crystalline form (3.7 g, yield: 74%).
Water t: 0.2%
Analysis of characteristics
The results of XRPD, DSC, and DVS analyses of the crystalline form prepared in
Example 4 are shown in FIGS. 1d, 2d, and 3d, respectively.
The peaks having a relative intensity (Me) of 5% or higher in the XRPD pattern of
the above crystalline forms are shown in Table 4 below. When the peaks had I/IO ratios
equal to or higher than 10%, they appeared at diffraction angles of 8.8°, 10.5 °, 11.1°,
146°, 155°, 175°, 192°, 194°, 203°, 208°, 210°, 222°, 231°, 234°, 250°, and
252° (26 i 0.2°).
[Table 4]
00 U16)
010.) at»
262 diffraction angte. d1 distance between crystal faces,
{/19 ('12): relative intensity (I indicates the intensity of each peak; 10 indicate
-_he_inLensitx 9f the highestflak.
Additionally, the above crystalline form showed an endothermic peak which has a
ng point at about 204.32°C and its highest point at about 208.34°C in a DSC
min). In the DSC, the endothermic peak indicates the g point. The melting
point was measured to be between about 205°C and about 207°C.
Additionally, in the DVS, the above lline form showed the hygroscopic level of
about 0.2% to about 0.5% in the region with a ve humidity of 10% to 90%. From
these results, the above crystalline forms were expected to be very stable in terms of
hygroscopicity. Additionally, from these results, it was confirmed that they were very
stable under a long-term storage condition (a temperature of 25°C and a relative
ty of 60%) and an accelerated condition (a temperature of 40°C and a relative
humidity of 75%).
Those of ordinary skill in the art will recognize that the present invention may be
embodied in other specific forms without departing from its spirit or essential charac—
teristics. The described embodiments are to be considered in all respects only as il—
lustrative and not ctive. The scope of the present invention is, therefore, indicated
by the appended claims rather than by the foregoing description. All changes which
come within the meaning and range of equivalency of the claims are to be embraced
within the scope of the present invention.
Claims (15)
- [Claim 1] A crystalline form of the compound of Formula 1 shown below: [Formula 1] \N OQNJL/ wk“ I /
- [Claim 2] The crystalline form of claim 1, wherein the lline form is anhydrous.
- [Claim 3] The crystalline form of claim 1, wherein the crystalline form is a hydrate.
- [Claim 4] The crystalline form of claim 3, n the hydrate is a dihydrate or a trihydrate.
- [Claim 5] The crystalline form of claim 1, wherein the crystalline form is a dihydrate having an X—ray powder diffraction (XRPD) pattern comprising peaks at diffraction angle 26 values of 8.6% 0.20, l6.0°i 0.20 and 17.2% 0.20 when irradiated with a Cu—Kor light source.
- [Claim 6] The crystalline form of claim 5, wherein the crystalline form further comprises peaks at diffraction angle 26 values of 9.4°i 0.20, 10.3% 0.20, 13.7% 0.20, 17.9% 0.20, 19.7% 0.20, 22.1% 0.20, 23.6% 0.20, and 26.4°i 0.20 when irradiated with a Cu-KOL light source.
- [Claim 7] The crystalline form of claim 1, wherein the crystalline form is a trihydrate having an X—ray powder diffraction pattern comprising peaks at diffraction angle 26 values of 5.3% 0.20 and l6.2°i 0.20 when ir— radiated with a Cu—Kor light .
- [Claim 8] The lline form of claim 7, wherein the crystalline form further comprises peaks at diffraction angle 26 values of 20.7°i 02°, 25 .4°i 0.20, and 28.50i 0.20 when irradiated with a Cu—Ka light source.
- [Claim 9] The crystalline form of claim 1, wherein the crystalline form is an anhydrous form having an X—ray powder diffraction n comprising peaks at diffraction angle 26 values of 3.8% 0.20 and ll.6°i 0.20 when irradiated with a Cu—Koz light source.
- [Claim 10] The crystalline form of claim 9, wherein the crystalline form further ses peaks at diffraction angle 26 values of 9.8°i 0.20, 16.9% 0.20, and 19.8% 0.20 when irradiated with a Cu-Ka light .
- [Claim 11] The crystalline form of claim 1, wherein the crystalline form is an anhydrous form having an X-ray powder diffraction pattern comprising peaks at diffraction angle 26 values of ll.l°J_r 0.20, 20.3% 0.20 and 208°: 02" when irradiated with a Cu-Ka light .
- [Claim 12] The crystalline form of claim 11, wherein the crystalline form further comprises peaks at diffraction angle 26 values of 14.601L 0.20, 15.5% 0.20, 21.0°i 0.2°, and 22.2°i 0.20 when irradiated with a Cu—Kd light source.
- [Claim 13] The crystalline form of any one of claims 1 to 12, wherein the crystalline form is substantially pure.
- [Claim 14] A pharmaceutical composition comprising a crystalline form according to any one of claims 1 to 13 and at least one pharmaceutically ac— le carrier or diluent.
- [Claim 15] The pharmaceutical composition of claim 14, wherein the pharma— ceutical composition is used for treating cancer d by epidermal growth factor receptor tyrosine kinase or a mutant thereof. Hfig.1AJ 2000 (CPS) Intensity _L OOO 3 10 20 30 40 2Theta e) (CPS) CDOO Intensity I\) OO 2Theta (Degree) 3 1o 20 30 40 2Theta (Degree) [
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0190854 | 2015-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ743659A true NZ743659A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018219967C1 (en) | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | |
CA2984724C (en) | Crystal of uracil compound | |
KR102342776B1 (en) | (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1 Polymorphic and solid forms of ,2-d][1,4]oxazepin-9-yl)amino)propanamide, and processes for their preparation | |
CN110088088B (en) | Novel crystal form of { [5- (3-chlorphenyl) -3-hydroxypyridine-2-carbonyl ] amino } acetic acid and preparation method thereof | |
ES2968174T3 (en) | Solid state form of ribociclib succinate | |
EP3263573B1 (en) | Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal | |
JP2018501289A (en) | Novel crystal form of neratinib maleate and process for producing the same | |
EA030142B1 (en) | Dasatinib salts | |
US10464946B2 (en) | Crystalline forms of thienopyrimidine compound | |
NZ743659A (en) | Crystalline forms of thienopyrimidine compound | |
WO2019008126A1 (en) | New crystalline form of a bcl-2 inhibitor, a process for its preparation and pharmaceutical compositions containing it | |
US11008333B2 (en) | Crystalline forms of hydrochloride salts of thienopyrimidine compound | |
CA3135152A1 (en) | Crystal form of acid addition salt of furopyrimidine compound | |
JP2022508864A (en) | Crystal form of maleate, a tyrosine kinase inhibitor, and its preparation method | |
WO2024009977A1 (en) | 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof | |
EA035346B1 (en) | 4-toluenesulfonic acid palbociclib salt, method for production thereof and use thereof in medicine | |
WO2017093773A1 (en) | New polymorphic and solvate form of idelalisib | |
CN112645929A (en) | Polymorphs of isopropylsulfonylphenylpyrimidines or salts thereof | |
NZ743660A (en) | Crystalline forms of hydrochloride salts of thienopyrimidine compound | |
TW201730178A (en) | New crystalline form of aripiprazole characterized in that the crystalline form has the property that the differential heat scan at a heating rate of 5 DEG C/min has an endothermic peak at a temperature of approximately 125 DEG C and close to 134 DEG C |